Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as already shown in adults and adolescents. Factor VIII inhibitor development was not detected during the study. Once-weekly efanesoctocog alfa was shown to…